investor's business daily

double trouble for rates | ibd weekly, september 07, 2026

here’s the prognosis for ai | ibd weekly, august 24, 2026

stock trading’s digital path | ibd weekly, august 17, 2026

the hazards of space junk | ibd weekly, july 27, 2026

mega musk nears takeoff | ibd weekly, september 14, 2026

private market reckoning | ibd weekly, may 25, 2026

a new future for nuclear | ibd weekly, june 29, 2026

google makes its move | ibd weekly, april 27, 2026

ai spending races ahead | ibd weekly, august 03, 2026

two sides to the ai megatrend | ibd weekly, june 01, 2026

investors prepare for act two | ibd weekly, august 31, 2026

the new military supply chain | ibd weekly, june 08, 2026

more spending, fewer people | ibd weekly, may 04, 2026

innovation nation | ibd weekly, july 06, 2026

chinks open in tech sites’ legal armor | ibd weekly, june 15, 2026

the most trusted financial companies | ibd weekly, september 28, 2026

a drug so hot it’s criminal | ibd weekly, may 11, 2026

say hello to cancer vaccines | ibd weekly, october 05, 2026

cybersecurity paradox | ibd weekly, august 10, 2026

the hiv challenge | ibd weekly, july 20, 2026